Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Search fresh public links, source activity, and ready-to-use post angles for $Qnrx.
Fresh curated links around $QNRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Revenue guidance slashed as commercial execution stumbles and academic spending weakens.
Record revenue of $214 million signals momentum ahead of gene therapy launches.
EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage.
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
Royalty receipts surged 14% as guidance raised for second consecutive quarter.
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.
Q2 2026 Reported Revenue of $6.6 Million, a 445% Increase Compared to Q2 2025Adjusted EBITDA (non-GAAP) Loss Reduced to $0.6 Million From $1.8 Million in Q1 2026Company Expects 202...
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnti...
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.